Evotec (EVO) said early Thursday its subsidiary, Just - Evotec Biologics, received a new grant from the Gates Foundation to help optimize monoclonal antibodies and other biological medicines.

Under the grant terms, the unit will leverage its molecular design suite of computational technologies, which integrate "advanced computational tools and high-throughput methodologies" to streamline the biologics development process, the company said.

The new investment will enable 10 new molecular design projects over the next three years, spanning the development of biotherapeutics that target multiple global health concerns.

Monoclonal antibodies are lab-made proteins that support the immune system in a targeted manner.